A Phase 3 interventional study of bempedoic acid in Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Esperion Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-01.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 2nd largest by enrollment, is one of 4 that started in 2017, is one of 7 in phase 3, and was the 12th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,462 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 2nd largest by enrollment, is one of 4 that started in 2017, is one of 6 in phase 3, and was the 12th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
bempedoic acid 180 mg tablet
Drug: bempedoic acid
bempedoic acid 180 mg tablets taken orally, once per day.
Also known as: ETC-1002
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.
Time frame: Up to Week 82
Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 72
Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 72
Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From OLE Baseline ApoB at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
Time frame: Baseline; Week 52 and Week 78
| Milestone | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid |
|---|---|---|
| Started | 492 | 970 |
| Completed | 459 | 913 |
| Not completed | 33 | 57 |
| Withdrew: Withdrawal by subject | 16 | 34 |
| Withdrew: Lost to follow-up | 7 | 5 |
| Withdrew: Adverse event | 7 | 14 |
| Withdrew: Study terminated by sponsor or investigator | 1 | 0 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Other | 1 | 1 |
TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.
| Participants | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Participants with TEAEs | 385 | 758 | 1143 |
| Participants with serious TEAEs | 97 | 202 | 299 |
| Participants with TEAEs of mild severity | 93 | 195 | 288 |
| Participants with TEAEs of moderate severity | 211 | 403 | 614 |
| Participants with TEAEs of severe severity | 81 | 160 | 241 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -12.82 ± 23.419 | -13.80 ± 25.018 | -13.47 ± 24.485 |
| Week 78 | -14.99 ± 23.660 | -14.15 ± 25.113 | -14.43 ± 24.632 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| milligrams per deciliter (mg/dL) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -14.08 ± 24.995 | -15.77 ± 28.123 | -15.19 ± 27.109 |
| Week 78 | -16.11 ± 25.628 | -16.04 ± 28.929 | -16.06 ± 27.862 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -10.60 ± 20.722 | -10.55 ± 22.682 | -10.57 ± 22.033 |
| Week 78 | -12.50 ± 22.081 | -10.82 ± 23.910 | -11.38 ± 23.321 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -9.01 ± 15.961 | -9.79 ± 16.893 | -9.53 ± 16.582 |
| Week 78 | -10.15 ± 16.541 | -9.34 ± 18.030 | -9.61 ± 17.545 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -7.5 ± 20.52 | -8.8 ± 21.89 | -8.4 ± 21.44 |
| Week 78 | -7.6 ± 22.15 | -7.0 ± 22.33 | -7.2 ± 22.26 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -11.553 (-53.120 to 44.167) | -19.709 (-52.617 to 34.151) | -16.476 (-52.874 to 41.667) |
| Week 78 | -15.005 (-50.510 to 44.000) | -18.065 (-51.701 to 50.505) | -16.740 (-51.577 to 48.279) |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -4.31 (-24.08 to 21.75) | -3.21 (-22.76 to 23.50) | -3.49 (-23.02 to 22.40) |
| Week 78 | -5.00 (-25.54 to 24.26) | -2.60 (-21.41 to 27.47) | -3.08 (-22.78 to 26.67) |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -4.54 ± 16.747 | -7.06 ± 15.638 | -6.20 ± 16.060 |
| Week 78 | -3.42 ± 17.555 | -4.91 ± 16.731 | -4.41 ± 17.018 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -12.4 ± 23.79 | 3.6 ± 27.49 | -1.8 ± 27.35 |
| Week 78 | -14.3 ± 25.79 | 3.7 ± 30.63 | -2.3 ± 30.31 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| mg/dL | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -14.7 ± 25.63 | 0.6 ± 24.92 | -4.6 ± 26.17 |
| Week 78 | -17.0 ± 28.56 | 0.2 ± 26.04 | -5.5 ± 28.08 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -10.0 ± 20.81 | 2.9 ± 23.98 | -1.4 ± 23.75 |
| Week 78 | -11.8 ± 23.08 | 3.1 ± 28.02 | -1.9 ± 27.38 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -8.7 ± 15.78 | 1.3 ± 17.23 | -2.1 ± 17.40 |
| Week 78 | -9.7 ± 17.39 | 2.1 ± 19.88 | -1.8 ± 19.88 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -10.0 ± 19.94 | 0.2 ± 21.48 | -3.2 ± 21.51 |
| Week 78 | -10.2 ± 21.84 | 2.4 ± 23.16 | -1.8 ± 23.49 |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -11.720 (-50.315 to 38.433) | -2.174 (-39.583 to 61.765) | -4.856 (-43.750 to 52.800) |
| Week 78 | -14.953 (-50.549 to 43.333) | 3.774 (-36.842 to 69.136) | -2.538 (-41.509 to 60.268) |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | 0.3 (-22.4 to 23.6) | 0.9 (-20.2 to 25.2) | 0.7 (-20.7 to 24.3) |
| Week 78 | -2.0 (-23.8 to 24.1) | 2.2 (-19.2 to 27.2) | 0.9 (-20.9 to 26.6) |
Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.
| percent change | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Week 52 | -4.3 ± 18.36 | -0.6 ± 14.88 | -1.8 ± 16.23 |
| Week 78 | -3.4 ± 17.77 | 2.7 ± 23.60 | 0.7 ± 22.01 |
Collected over Up to Week 82. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo; Bempedoic Acid | 3/492 (0.6%) | 97/492 (19.7%) | 108/492 (22%) |
| Bempedoic Acid; Bempedoic Acid | 10/970 (1%) | 202/970 (20.8%) | 201/970 (20.7%) |
| OLE Bempedoic Acid | 13/1,462 (0.9%) | 299/1,462 (20.5%) | 309/1,462 (21.1%) |
| Event | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 3/492 | 15/970 | 18/1462 |
| Atrial fibrillationCardiac disorders | 2/492 | 12/970 | 14/1462 |
| PneumoniaInfections and infestations | 6/492 | 9/970 | 15/1462 |
| Angina unstableCardiac disorders | 3/492 | 10/970 | 13/1462 |
| Angina pectorisCardiac disorders | 5/492 | 9/970 | 14/1462 |
| Non-cardiac chest painGeneral disorders | 1/492 | 8/970 | 9/1462 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/492 | 6/970 | 10/1462 |
| Inguinal herniaGastrointestinal disorders | 4/492 | 1/970 | 5/1462 |
| Peripheral ischaemiaVascular disorders | 4/492 | 0/970 | 4/1462 |
| Acute myocardial infarctionCardiac disorders | 2/492 | 7/970 | 9/1462 |
| Event | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | OLE Bempedoic Acid |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 33/492 | 86/970 | 119/1462 |
| Urinary tract infectionInfections and infestations | 40/492 | 49/970 | 89/1462 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 30/492 | 38/970 | 68/1462 |
| Upper respiratory tract infectionInfections and infestations | 18/492 | 49/970 | 67/1462 |
Baseline data are reported for members of the Safety Population, comprised of all enrolled participants who received at least 1 dose of bempedoic acid in the Open-Label Extension (OLE) Study.
| Age, Continuous(years) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 67.5 ± 8.54 | 66.5 ± 8.81 | 66.9 ± 8.73 |
| Sex: Female, Male(Participants) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Female | 142 | 239 | 381 |
| Male | 350 | 731 | 1081 |
| Race (NIH/OMB)(Participants) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 5 | 9 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 6 | 23 | 29 |
| White | 480 | 931 | 1411 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Low-density lipoprotein cholesterol (LDL-C): Parent Study(milligrams per deciliter (mg/dL)) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 98.96 ± 24.171 | 102.94 ± 29.899 | 101.60 ± 28.156 |
| Non-high-density lipoprotein cholesterol (N-HDL-C): Parent Study(mg/dL) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 126.41 ± 28.531 | 130.09 ± 34.727 | 128.85 ± 32.809 |
| Total cholesterol: Parent Study(mg/dL) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 175.33 ± 30.026 | 178.94 ± 36.057 | 177.73 ± 34.179 |
| Apolipoprotein B: Parent Study(mg/dL) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 85.1 ± 19.25 | 88.2 ± 21.71 | 87.2 ± 20.97 |
| High-sensitivity C-reactive protein (hs-CRP): Parent Study(milligrams per Liter (mg/L)) | Placebo; Bempedoic Acid | Bempedoic Acid; Bempedoic Acid | Total |
|---|---|---|---|
| Median | 1.515 (0.810 to 3.490) | 1.500 (0.700 to 3.220) | 1.510 (0.750 to 3.320) |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Nov 2019, 33 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 33 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid